Biogen has announced a broad collaboration and alliance with the University of Pennsylvania to advance gene therapy and gene editing technologies in a deal valued up to $2 billion. The research and translational development collaboration has multiple objectives, but will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle, and the central nervous system. Another important aspect of the alliance will focus on validating gene transfer technology using adeno-associated virus (AAV) gene-delivery vectors. The collaboration will also explore the expanded use of genome-editing technology (i.e., the insertion, deletion or replacement of DNA in the genome of an organism) as a potential therapeutic platform.

Biogen will work with James Wilson, MD, PhD., Professor of Medicine and Pediatrics, and Director of Penn's Gene Therapy Program, and Jean Bennett, MD, PhD, Professor of Ophthalmology and Cell and Developmental Biology and Director of the Center for Advanced Retinal and Ocular Therapeutics. Both are recognized leaders in gene therapy in the Perelman School of Medicine at the University of Pennsylvania.

Under the agreement, Penn may receive up to $2 billion in research funding, options, and milestone payments. Biogen will make an upfront payment to Penn of $20 million with an additional $62.5 million committed to fund R&D costs extending over the next three to five years in seven distinct preclinical research and development programs conducted by the Wilson and Bennett laboratories. Each program may trigger milestones that range from $77.5 million to $137.5 million per product as well as royalties payable on net sales of products. Biogen also receives an option to license AAV vectors for certain indications from Penn for Biogen's use outside of the collaboration.

Under this broad research and development alliance, Penn will combine its gene-therapy resources and expertise to develop therapeutic candidates under the various collaboration programs using both existing and newly developed AAV vectors and will also aid in the development of new manufacturing approaches needed to support commercialization of gene-therapy products. Biogen will in turn, leverage both its therapeutic area and target identification expertise and drug-development capabilities to help advance the collaboration programs into the clinic and toward approval. In addition to developing AAV gene-replacement programs, the collaboration will also explore new therapeutic targets using AAV vectors and genome-editing technologies. Biogen expects these AAV gene-transfer capabilities to be important for future gene-therapy products and to pursue application of genome-editing technology for numerous disease indications.

Separate from the agreement, Biogen is also entering into a license agreement with Regenxbio, a Rockville, Maryland-based biotechnology company, for the exclusive rights to use adeno-associated virus serotype 8 (AAV8) or 9 (AAV9) technologies developed in Dr. Wilson's laboratory, for which Regenxbio holds a worldwide patent license from Penn. The AAV8 and AAV9 technologies will be used in ophthalmic collaboration programs with Penn.

Source: Biogen